Borderline ovarian serous tumor
MONDO:0020662A low grade serous epithelial neoplasm arising from the ovary. It is characterized by an atypical proliferation of serous-type epithelial cells without evidence of stromal invasion. It is often asymptomatic but rarely it may present with abdominal pain or abdominal enlargement due to rupture or torsion.
Also known as: borderline ovarian serous neoplasm, borderline ovarian serous tumor, borderline serous neoplasm of ovary, borderline serous neoplasm of the ovary, borderline serous tumor of ovary, borderline serous tumor of the ovary, borderline serous tumour of ovary, borderline serous tumour of the ovary
1449 clinical trials for this condition and its sub-types, 11 tagged with Borderline ovarian serous tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Phase 3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the drugs can shrink tumors or control the cancer. Researchers will also monitor side…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a nurse check on you from home? new study tests remote monitoring for rare cancers
Knowledge-focused Recruiting nowThis study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC